Novomix 30 is a biphasic insulin aspart injection (recombinant human insulin analog), which contains 30% soluble insulin aspart (rapid-acting)and 70% prota mine-crystallised insulin aspart (intermediate-acting). Soluble insulin aspart (30%) has a rapid onset of action, thus allowing it to be given closer to a meal (within zero to 10 minutes of the meal) when compared to soluble human insulin; the protamine-crystallised insulin aspart (70% ), crystalline phase- which has an activity profile that is similar to that of human NPH insulin. When Novomix 30 is injected subcutaneously, the onset of action will occur within 10 to 20 minutes of injection. The maximum effect is exerted between 1 and 4 hours after injection. The duration of action is up to 24 hours. Mode of action: See under the text of insulin
asp art.

Ind: Treatment of diabetes mellitus in adults, adolescents and children aged 10 to 17 years.

C/I; S/E; Precautions: See under the text of insulin.

Dosage & admin: Novomix 30 dosing is individual and determined in accordance with the needs of the patient. Blood glucose monitoring and insulin dose adjustments are recommended to achieve optimal glycaemic control. In patients with type 2 diabetes Novomix 30 can be given as monotherapy. Novomix 30 can also be given in combination with oral antidiabetic medicinal products if the patient's blood glucose is inadequately controlled with oral antidiabetic medicinal products alone. For patients with type 2 diabetes, the recommended starting dose of Novomix 30 is 6 units at breakfast and 6 units at dinner (evening meal). Novomix 30 can also be initiated once daily with 12 units at dinner (evening meal). When using Novomix 30 once daily, it is generally recommended to move to twice-daily when reaching 30 units by splitting the dose into equal breakfast and dinner doses. If twice daily dosing with Novomix 30 results in recurrent daytime hypoglycaemic episodes, the morning dose can be split into morning and lunchtime doses (thrice daily dose). The following titration guideline is recommended for dose adjustments: Pre-meal blood glucose level- Novomix 30 dose adjustment . The lowest of three previous days' pre-meal levels should be used. The dose should not be increased if hypoglycaemia occurred within these days. Dose adjustments can be made once a week until target HbAlc is reached. Pre-meal blood glucose levels should be used to evaluate the adequacy of the preceding dose. The combination of Novomix 30 with pioglitazone should only be considered followi.ng clinical evaluation of the patient's risk of developing signs or symptoms of fluid-related adverse reactions. The initiation of Novomix 30 should be undertaken cautiously titrating to the lowest dose required to achieve glycaemic control. In patients with type 1 diabetes the individual insulin requirement is usually between 0.5 and 1.0 units/kg/day. Novomix 30 may fully or partially meet this requirement. The daily insulin requirement may be higher in patients with insulin resistance ( e.g due to obesity), and lower in patients with residual endogenous insulin production.

Drug inter: See under the text of insulin.

Note: For further information please consult manufacturer's literature.

3ml penfill cartridge x 5's pack: 3875.00 MRP